Most people think about dementia as something that either happens or doesn’t, an unpredictable fate sealed by genetics and age. But a growing body of research is painting a fundamentally different picture: one in which the seeds of Alzheimer’s disease are planted decades before any symptom appears, and the soil conditions matter.
A new study published in Neurology Open Access in June 2026 adds a striking data point to that picture. Using the famous Framingham Heart Study cohort, researchers measured vitamin D levels in adults with an average age of 39 and then, 16 years later, scanned their brains for early signs of Alzheimer’s disease. What they found was clear and concerning: people with lower vitamin D in their late 30s had significantly more tau protein deposited in their brains in their mid-50s, even though none of them had developed dementia.
The findings suggest that vitamin D levels in early midlife, a period most people never associate with dementia risk, may matter far more than previously understood.
Why Tau Matters: Reading the Brain Before Dementia Begins
Alzheimer’s disease does not begin with memory loss. It begins with molecular changes in the brain that accumulate over decades before becoming clinically apparent. Two of the most important of these changes are the buildup of amyloid plaques, sticky protein deposits between neurons, and tau tangles, twisted threads of a protein called tau that accumulate inside neurons and disrupt their function.
Modern brain imaging technology, specifically PET scanning, can detect both amyloid and tau in living people long before symptoms develop. This makes tau-PET and amyloid-PET scans powerful tools for studying what researchers call “preclinical dementia,” the invisible, decades-long phase of disease that precedes any clinical diagnosis.
Tau is particularly significant because it follows a predictable spatial pattern as Alzheimer’s progresses. It typically accumulates first in the entorhinal cortex, a region critical for memory formation, before spreading to adjacent structures, including the parahippocampal gyrus, fusiform gyrus, and amygdala. These earliest-affected regions are exactly the ones the researchers used to define their “composite tau” outcome measure in this study.
The fact that lower vitamin D at age 39 was associated with greater tau in precisely these early-affected brain regions 16 years later makes this finding particularly significant from a preventive medicine standpoint.
How the Study Was Designed
The study drew on data from the Framingham Heart Study Generation 3 cohort, the third generation of participants in one of the longest-running cardiovascular studies in medical history. Participants had their blood vitamin D levels measured between 2002 and 2005 (examination cycle 1), at an average age of 39. They then underwent tau-PET and/or amyloid-PET brain imaging between 2016 and 2019.
The final analytical sample included 793 dementia-free individuals: 369 had tau-PET, and 424 had amyloid-PET. None had dementia, stroke, or other known neurological conditions at the time of brain imaging, making this a truly preclinical sample.
Vitamin D was measured as serum 25-hydroxyvitamin D (25(OH)D), the standard clinical marker of vitamin D status. The researchers then used statistical models adjusted for age, sex, body mass index, blood pressure, diabetes, cardiovascular disease, depression, smoking, and the season in which blood was collected, accounting for the well-known seasonal variation in vitamin D levels due to sun exposure.
The key finding: higher baseline serum 25(OH)D was significantly associated with lower global tau-PET burden 16 years later (β = −0.022; p = 0.010). The same protective association was found for composite tau — the specific early-affected brain regions (β = −0.023; p = 0.016). These associations held up across multiple statistical models and remained consistent when participants taking vitamin D supplements were excluded from the analysis.
Notably, no significant association was found between vitamin D and amyloid deposition on brain-PET. The researchers suggest this may reflect the known sequence of Alzheimer’s pathology: tau begins accumulating in medial temporal regions earlier in the disease process than cortical amyloid does, making tau more detectable at younger ages, even in preclinical populations.
This Is the First Study of Its Kind in Early Midlife
Previous research establishing links between vitamin D and dementia risk has almost exclusively focused on older adults, typically those aged 60 to 75. Studies have consistently shown that low vitamin D in later life is associated with a 36% to 58% increased risk of Alzheimer’s disease, with a dose-response relationship between severity of deficiency and magnitude of risk.
What has been missing is evidence from younger people, before any clinical symptoms emerge, and specifically evidence linking vitamin D to the neuroimaging biomarkers of preclinical disease rather than to clinical diagnosis.
This study fills that gap. With a mean age of 39 at vitamin D measurement and brain PET imaging approximately 16 years later (mean age around 55), it represents the first investigation of vitamin D in genuinely early midlife and its relationship to preclinical dementia markers. The researchers explicitly note that no previous study has evaluated this association using tau-PET or amyloid-PET as outcome measures.
How Vitamin D May Protect the Brain: The Biology
The study’s findings are not biologically surprising when you consider what vitamin D does in the nervous system. Vitamin D receptors are distributed throughout the brain, including in the hippocampus, the region central to memory consolidation and among the earliest affected in Alzheimer’s. The enzyme required to activate vitamin D is also present in the brain, meaning the nervous system can both sense and respond to vitamin D locally, not just in the rest of the body.
Several mechanisms have been proposed for how vitamin D protects against tau pathology specifically:
Antioxidant defense. Vitamin D deficiency reduces the brain’s antioxidant capacity, specifically by downregulating enzymes such as superoxide dismutase and glutathione peroxidase, thereby increasing oxidative stress. Oxidative stress is strongly linked to tau hyperphosphorylation, the abnormal modification that makes tau proteins aggregate into tangles.
Kinase regulation. Vitamin D deficiency increases the activity of enzymes called CDK5 and GSK3β, which phosphorylate tau at key sites associated with Alzheimer’s pathology (including Thr181, Thr205, and Ser396). Higher vitamin D helps suppress this aberrant phosphorylation activity.
Neuroinflammation. Vitamin D modulates the immune response in the brain, reducing inflammatory cytokine production and strengthening anti-inflammatory defenses. Neuroinflammation is now understood to accelerate tau pathology and neuronal damage.
Protein phosphatase regulation. Vitamin D appears to influence the activity of protein phosphatase 2A (PP2A), an enzyme that removes phosphate groups from tau. Reduced PP2A activity allows tau to accumulate in its hyperphosphorylated, aggregation-prone form.
Laboratory evidence from animal models supports these mechanisms: transgenic mice fed vitamin D-deficient diets showed increased tau phosphorylation and greater neuronal loss, while supplementation with vitamin D3 in similar models reduced both tau and amyloid burden and improved cognitive performance.
What About Vitamin D Supplements?
The study raises an obvious practical question: if low vitamin D in midlife predicts greater tau accumulation later, does taking vitamin D supplements offer protection?
The honest answer is: the evidence is promising but not yet definitive. Several clinical trials have shown cognitive benefits of vitamin D supplementation, particularly in people who are already deficient. In one trial, vitamin D supplementation at 800 IU per day over 12 months significantly improved cognitive function in older adults with mild cognitive impairment. In another, higher-dose supplementation (4,000 IU/day vs 400 IU/day) produced greater improvements in visual memory, particularly in people with baseline vitamin D levels below 30 ng/mL.
A meta-analysis of 24 randomized controlled trials found a small but significant positive effect of vitamin D supplementation on global cognition, with stronger effects in those who were deficient at baseline.
What this study uniquely contributes is a rationale for acting on vitamin D in early midlife rather than waiting until older age, when pathological changes may already be substantially entrenched. The window of opportunity for disease modification is larger at 39 than at 70.
The researchers are appropriately cautious: they call for formal clinical trials to test whether correcting low vitamin D in midlife reduces future tau accumulation or dementia risk. That evidence does not yet exist. But the biological plausibility is strong, and the risk of maintaining adequate vitamin D levels through sun exposure, diet, or supplementation is low.
Important Limitations
The study population was predominantly White, limiting the generalizability of the findings. Vitamin D was measured only once, at baseline, meaning changes over the 16-year follow-up period are not captured. Only 22 participants were taking vitamin D supplements at baseline (reflecting the cohort’s relatively young age), so analyses of supplementation effects were underpowered. And as with all observational studies, residual confounding from unmeasured factors cannot be entirely excluded.
These limitations do not undermine the core finding; they define the agenda for the next generation of research.
The Takeaway
A single vitamin D blood test taken when someone was in their late 30s predicted measurably different levels of Alzheimer ‘s-related brain changes 16 years later. The difference was not observed for amyloid.
This does not mean that taking vitamin D supplements will prevent Alzheimer’s. That requires clinical trial evidence that does not yet exist. But it does mean that vitamin D status in early midlife deserves more attention than it currently receives as a potentially modifiable risk factor for dementia, one that is cheap to measure, straightforward to address, and now linked to objective neuroimaging changes in the preclinical phase of the most common dementia in the world.
Check your levels. Talk to your doctor. The conversation is worth having at 39, not 79.
Reference:
Mulligan, M. D., Scott, M. R., Yang, Q., Wang, R., Ghosh, S., Johnson, K. A., Beiser, A. S., Seshadri, S., & McGrath, E. R. (2026). Association of circulating vitamin D in midlife with increased tau-PET burden in dementia-free adults. Neurology Open Access, 2, e000057. https://doi.org/10.1212/WN9.0000000000000057